Abstract
Background The rise in antibody titers against the novel coronavirus (SARS-CoV-2), and its duration is considered an important indicator for confirming the efficacy of the COVID-19 vaccine, and self-paid tests of antibody titer are conducted at many facilities nationwide.
Methods The relationship between the number of days after the second and third dose of vaccines, age, and antibody titer was determined from the medical records of general internal medicine clinics that conducted self-paid testing of SARS-CoV-2 antibody titer using Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics), as well as the relationship between the number of days after two or more dose of vaccines and antibody titer. We also examined antibody titers in cases of spontaneous infection with SARS-CoV-2 after two or more doses of the vaccine.
Results Age and antibody titer were negatively correlated in 86 subjects whose antibody titer was measured within 1 month after the second vaccination with the COVID-19 vaccine. In 31 subjects whose antibody titer was measured within one month after the third dose of vaccine, age and antibody titer showed a negative correlation (p<0.01). The mean antibody titer after the third vaccination was 20704.9±16820.7 U/mL, more than 10 times the mean antibody titer after the second dose of vaccine of 1601.9±1297.9 U/mL. There were also cases of infection after the third or fourth dose of vaccine, with antibody titers in the tens of thousands after infection, but they still received further booster vaccinations after infection.
Discussion SARS-CoV-2 antibody titers measured within 1 month of the second or third dose of vaccine showed a negative correlation with age, and antibody titers also showed a negative correlation trend with the number of days after the second dose of vaccine. It is considered that many people in Japan received further booster vaccinations after spontaneous infection, even though they already had antibody titers in the tens of thousands U/mL by “hybrid immunity” after spontaneous infection following two or more dose of vaccine.
Conclusion After measuring SARS-CoV-2 antibody titers, booster vaccination of those with low antibody titers should be done on a priority basis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocols were approved by the ethics committee of Osaka Dental University Hospital (2022-10).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at
